Polyclonal immunoglobulin therapeutics comprising dosed IgG and IgM combinations are powerful tools in fighting cancer and severe infections. The inability of protein ligands to produce polyclonal IgG- and IgM-enriched formulations and recover monoclonal IgM calls for novel ligands with superior biorecognition activity. In this study, a peptoid ligand discovered by our group, and integrated into affinity adsorbents LigaTrap “Human IgG” and “Human IgM”, is utilized to purify IgG and IgM from complex fluids. IgG purification from human serum using LigaTrap IgG afforded 94.6% purity and 62.9% yield, on par with Protein A/G resins. When challenged with CHO and HEK cell culture harvests with low IgG titer (< 1 mg/mL), LigaTrap IgG returned values of yield and purity well above 60% and 90%. LigaTrap IgM was evaluated for purifying IgM in comparison with commercial adsorbents, and afforded a product purity of 93% from a CHO harvest (IgM titer of 1 mg/mL) and 75.1% yield from a HEK harvest (0.5 mg/mL). LigaTrap-M provided IgM enrichment up to 11-fold higher than HiTrap resin. The peptoid adsorbents separated IgG-depleted human serum into IgM- and IgA-enriched fractions. These results demonstrate the potential of the peptoid ligand for manufacturing polyclonal Ig formulations and monoclonal IgM therapeutics.

包含IgG和IgM组合剂量的多克隆免疫球蛋白疗法是抵抗癌症和严重感染的有力工具。蛋白配体不能产生富含多克隆IgG和IgM的制剂并无法回收单克隆IgM，因此需要具有出色生物识别活性的新型配体。在这项研究中，我们小组发现的类肽配体被整合到亲和吸附剂LigaTrap“人IgG”和“人IgM”中，用于从复杂液体中纯化IgG和IgM。与蛋白A / G树脂相比，使用LigaTrap IgG从人血清中纯化IgG可获得94.6％的纯度和62.9％的产率。当用低IgG滴度（<1 mg / mL）的CHO和HEK细胞培养物挑战时，LigaTrap IgG的产率和纯度值远高于60％和90％。，并且从CHO收获物中获得的产品纯度为93％（IgM滴度为1 mg / mL），从HEK收获物中获得的产品纯度为75.1％（0.5 mg / mL）。LigaTrap-M提供的IgM富集度比HiTrap树脂高11倍。类肽吸附剂将消耗IgG的人血清分离为富含IgM和IgA的馏分。这些结果证明了类肽配体在生产多克隆Ig制剂和单克隆IgM治疗剂中的潜力。